Liraglutide

BreastfeedingPediatric
  • TRADE NAMES: Saxenda (Novo Nordisk); Victoza (Novo Nordisk); Xultophy (Novo Nordisk)
  • INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus (Victoza); adjunct to diet and exercise for chronic weight management (Saxenda)
  • CLASS: Glucagon-like peptide-1 (GLP-1) receptor agonist
  • HALF-LIFE: 13 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Acetaminophen, Atorvastatin, Digoxin, Griseofulvin, Lisinopril, Warfarin

PREGNANCY CATEGORY: C

Contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.

Xultophy is liraglutide and insulin degludec.

RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

Our database has 49 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
RENAL
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of the cardiovascular safety of liraglutide in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 01/19/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric